Skip to main content
. 2015 Jul 6;10(7):e0132348. doi: 10.1371/journal.pone.0132348

Fig 6. A2BR agonist-treated dendritic cells acquired increased ability to stimulate γδ and Th17 autoreactive T cells.

Fig 6

A) Splenic APCs isolated from A2BR agonist-treated, immunized B6 mice have stronger ability stimulating γδ, and Th17 autoreactive T cells. Responder T cells were isolated from immunized B6 mice 13 days post immunization. After a 3-day co-incubation of T cells and splenic APCs, the activated T cells were separated by Ficoll gradient centrifugation and staining for γδ T cells or Th17 cells. B) A2BR agonist-treated BMDCs acquired increased stimulating activity to stimulate γδ, and Th17 autoreactive T cells. BMDCs were cultured from bone marrow cells of immunized B6 mice. After a 5 day co-culture of in vivo primed responder T cells with A2BR agonist-treated and-untreated BMDCs in the presence of immunizing peptide, the number of γδ T cells and IL-17+ T cells among activated T cells were examined (B) and the IL-17 and IFN-γ amounts in 48 h-stimulated culture supernatants were compared (C). **p< 0.01.